GlassScriptPhysician profile
Joseph Simodynes
NPI 1770620031
$2,827.91
in general payments reported to CMS, 2019-2025
26 companies · $491 in 2025
The $491 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $318 · 2021: $38.18 · 2022: $88.01 · 2023: $487 · 2024: $704 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $651.10 | 2019-2025 | |
| Abbvie INC. | $405.84 | 2019-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $245.42 | 2024 | Sotyktu |
| Janssen Biotech, INC. | $186.55 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $170.65 | 2020-2023 | Winlevi, Ilumya |
| Lilly USA, LLC | $150.97 | 2019-2022 | |
| Pfizer INC. | $148.73 | 2019-2024 | |
| Leo Pharma INC. | $114.55 | 2022-2025 | Adbry |
| Ucb, INC. | $87.10 | 2020-2024 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $79.48 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $78.82 | 2019 | |
| Organon LLC | $74.19 | 2025 | Vtama |
| Dermavant Sciences, INC. | $70.02 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $61.66 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.92 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $56.24 | 2023-2025 | Puraply, Puraply Wound Matrix |
| Galderma Laboratories, L.P. | $38.02 | 2020-2024 | |
| Amgen INC. | $23.88 | 2019 | |
| Kyowa Kirin, INC. | $23.56 | 2025 | |
| Genzyme Corporation | $19.15 | 2019 | |
| Almirall LLC | $18.66 | 2025 | Klisyri |
| Biofrontera INC. | $18.12 | 2019 | |
| Aclaris Therapeutics, INC. | $17.24 | 2019 | |
| Celgene Corporation | $14.96 | 2019 | |
| Mayne Pharma Commercial LLC | $12.20 | 2019 | |
| Prugen, INC. Pharmaceuticals | $2.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Simodynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.